Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Khunti K, et al. Among authors: shimomura i. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1. Diabetes Obes Metab. 2020. PMID: 31468637 Free PMC article.
Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump.
Kuroda A, Yasuda T, Takahara M, Sakamoto F, Kasami R, Miyashita K, Yoshida S, Kondo E, Aihara K, Endo I, Matsuoka TA, Kaneto H, Matsumoto T, Shimomura I, Matsuhisa M. Kuroda A, et al. Among authors: shimomura i. Diabetes Technol Ther. 2012 Nov;14(11):1077-80. doi: 10.1089/dia.2012.0109. Diabetes Technol Ther. 2012. PMID: 23101953
Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes.
Nakatsuji H, Kishida K, Kobayashi H, Funahashi T, Shimomura I; Senri Study II Group. Nakatsuji H, et al. Among authors: shimomura i. Diabetes Res Clin Pract. 2013 Jan;99(1):e14-7. doi: 10.1016/j.diabres.2012.10.003. Epub 2012 Nov 9. Diabetes Res Clin Pract. 2013. PMID: 23142017 Clinical Trial.
Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial. Katakami N, et al. Among authors: shimomura i. J Atheroscler Thromb. 2013;20(12):893-902. doi: 10.5551/jat.18333. Epub 2013 Aug 20. J Atheroscler Thromb. 2013. PMID: 23965491 Free article. Clinical Trial.
720 results